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STUDY PROTOCOL

Reshaping the path of mild cognitive
impairment by refining exercise prescription:
a study protocol of a randomized controlled trial
to understand the “what,” “for whom,” and “how”
of exercise to promote cognitive function
Cindy K. Barha1,2,3, Ryan S. Falck1,2,3, John R. Best4,5,6, Lindsay S. Nagamatsu7,8, Ging‑Yuek Robin Hsiung2,9,
A. William Sheel10, Chun Liang Hsu11, Arthur F. Kramer12,13, Michelle W. Voss14,15, Kirk I. Erickson16,17,18,
Jennifer C. Davis3,19, J. Kevin Shoemaker7, Lara Boyd1,2, Rachel A. Crockett1,2,3, Lisanne ten Brinke1,2,3,
Louis Bherer20,21,22, Joel Singer23,24, Liisa A. M. Galea2,25, Claudia Jacova26, Alexis Bullock1,2,3, Sofia Grant1,2,3 and
Teresa Liu‑Ambrose1,2,3*   

Abstract
Background: Targeted exercise training is a promising strategy for promoting cognitive function and preventing
dementia in older age. Despite the utility of exercise as an intervention, variation still exists in exercise-induced cogni‑
tive gains and questions remain regarding the type of training (i.e., what), as well as moderators (i.e., for whom) and
mechanisms (i.e., how) of benefit. Both aerobic training (AT) and resistance training (RT) enhance cognitive function
in older adults without cognitive impairment; however, the vast majority of trials have focused exclusively on AT. Thus,
more research is needed on RT, as well as on the combination of AT and RT, in older adults with mild cognitive impair‑
ment (MCI), a prodromal stage of dementia. Therefore, we aim to conduct a 6-month, 2 × 2 factorial randomized
controlled trial in older adults with MCI to assess the individual effects of AT and RT, and the combined effect of AT
and RT on cognitive function and to determine the possible underlying biological mechanisms.
Methods: Two hundred and sixteen community-dwelling adults, aged 65 to 85 years, with MCI from metropolitan
Vancouver will be recruited to participate in this study. Randomization will be stratified by biological sex and partici‑
pants will be randomly allocated to one of the four experimental groups: (1) 4×/week balance and tone (BAT; i.e.,
active control); (2) combined 2×/week AT + 2×/week RT; (3) 2×/week AT + 2×/week BAT; or (4) 2×/week RT + 2×/
week BAT. The primary outcome is cognitive function as measured by the Alzheimer’s Disease Assessment Scale-Cog‑
nitive-Plus. Secondary outcomes include cognitive function, health-related quality of life, physical function, actigraphy
measures, questionnaires, and falls. Outcomes will be measured at baseline, 6 months (i.e., trial completion), and 18
months (i.e., 12-month follow-up).
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Discussion: Establishing the efficacy of different types and combinations of exercise training to minimize cognitive
decline will advance our ability to prescribe exercise as “medicine” to treat MCI and delay the onset and progression of
dementia. This trial is extremely timely as cognitive impairment and dementia pose a growing threat to global public
health.
Trial registration: ClinicalTrials.gov NCT02737878. Registered on April 14, 2016.
Keywords: Randomized controlled trial, Mild cognitive impairment, Aerobic training, Resistance training, Cognition,
Mobility, Biomarkers, Exercise

Introduction
Dementia is one of the most pressing health care issues
of the twenty-first century. Individuals with cognitive
impairment and dementia have reduced quality of life
as they lose their functional independence [1]. As the
proportion of the population over 65 years continues to
increase, dementia will place increasing demands and
costs on the public health system [2]. Thus, the societal
value of identifying and developing effective intervention and prevention strategies cannot be overstated [3].
If the onset and progression of dementia were delayed by
1 year, there would be 9 million fewer cases by 2050 [3].
Effective pharmacologic treatment of dementia remains
a major challenge [4]. Exercise is a promising strategy for
preventing dementia [5]. Notably, exercise significantly
reduces key cardiometabolic risk factors for dementia
[6, 7], such as hypertension and type 2 diabetes, for both
Alzheimer’s disease and vascular cognitive impairment—
the two most common types of dementia.
Broadly, there are two distinct forms of exercise: (1)
aerobic training (AT; e.g., running), aimed at improving
cardiovascular health; and (2) resistance training (RT;
e.g., lifting weights), aimed at improving muscle strength.
Each type of exercise training has its own distinct physiology and benefits [8]. Evidence from randomized controlled trials (RCTs) suggests that both AT and RT
enhance cognitive function in older adults without cognitive impairment and dementia [9, 10]. However, questions regarding the type of training (i.e., what), as well as
moderators (i.e., for whom) and mechanisms (i.e., how)
of benefit still remain [11, 12].
In regard to what type of exercise, the majority of published RCTs have focused solely on AT [9, 13]. Thus,
more research is needed on RT, as well as on the combination of AT and RT. Importantly, to our knowledge,
there is no single published high-quality RCT that has
examined both the individual and combined effects of
AT and RT on cognitive function in older adults. Establishing the efficacy of different types and combinations of
exercise training will advance our understanding of how
to best prescribe exercise to attenuate cognitive decline.
For example, exercise prescription could be personalized according to deficits in specific cognitive domains.

For those who do not have the mobility to uptake AT, RT
could be recommended as an evidence-based alternative.
For whom exercise benefits, there is good evidence that
targeted exercise training improves cognitive function
in healthy older adults [9, 10, 14–16]. However, the role
of exercise interventions among those at increased risk
for dementia, such as older adults with mild cognitive
impairment (MCI), is not well established [14, 17–21].
Currently, there is wide recognition that MCI represents
the prodromal stage of Alzheimer’s disease, vascular cognitive impairment, and mixed dementia [22–25]. MCI is
a clinical entity characterized by cognitive decline greater
than that expected for an individual’s age and education
level but that does not interfere notably with everyday
function [26]. Individuals with MCI are at increased risk
for dementia [22]; those with MCI develop Alzheimer’s
disease at a rate between 10 and 30% annually [27, 28],
whereas those without MCI develop dementia at a rate
between 1 and 2% annually [27]. Evidence also suggests that older adults with MCI experience significant
declines in quality of life [1, 29]. Thus, older adults with
MCI represent an ideal target population for intervention
strategies, as the preservation of their cognitive function
will likely prolong their ability to live independently and
with quality.
Evidence suggests older females may reap greater cognitive gains from AT than older males, particularly in the
cognitive domain of executive functions [10, 13, 30–32].
Much of this evidence comes from meta-analyses comparing RCTs of AT that have a high percentage of older
females to RCTs with low percentage of older females
(i.e., data not disaggregated by biological sex) [13, 33].
Direct RCT evidence is restricted to post hoc analyses [30–32], which are not definitive because statistical power is lacking. Moreover, whether there are sex
differences in the effect of RT on cognition is largely
unexplored.
Our current understanding of how exercise promotes
cognitive function in humans is limited and largely
focuses on central induction of neurotrophic factor
cascades, such as brain-derived neurotrophic factor
(BDNF) and insulin-like growth factor (IGF-1). Evidence
from rodent models suggests different types of exercise

Barha et al. Trials

(2022) 23:766

training may promote cognitive health through divergent
pathways, with AT preferentially increasing BDNF and
RT preferentially increasing IGF-1 [34]. In humans, AT
increases peripheral BDNF levels [35, 36] and, while less
studied, RT increases IGF-1 [37, 38].
AT and RT may also promote cognitive function
through parallel pathways, including reducing peripheral
and central inflammation, which is associated with the
pathogenesis of MCI [39]. Indeed some evidence supports the ability of AT and RT to reduce circulating levels
of certain inflammatory markers in those with MCI [40].
Gaining insights into the underlying biological mechanisms will enable the refinement of existing exercise
recommendations. For example, if RT preferentially
increases IGF-1 compared with AT, then RT may be
the more appropriate recommendation for individuals
with the BDNF Val66met polymorphism, a common single-nucleotide polymorphism resulting in reduced activity-dependent secretion of the mature form of BDNF
[41].
Thus, we aim to conduct a 2 × 2 factorial RCT of exercise in community-dwelling older adults with MCI. Our
primary objective is to assess the individual effects of AT

Fig. 1 Overview of study design from recruitment to follow-up
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and RT, as well as the combined (i.e., interaction) effect
of the two types of exercise training on cognitive function, as measured by the Alzheimer’s Disease Assessment
Scale-Cognitive-Plus (ADAS-Cog-Plus). The secondary objective is to assess sex differences. The tertiary
objectives are to explore the mechanisms underlying the
individual and interaction effects of AT and RT, and to
explore the potential moderation of effects by the BDNF
Val66Met polymorphism.

Methods
Design and setting

We will conduct a single-blinded, superiority, 2×2 factorial-arm RCT in a research center (Vancouver, British
Columbia, Canada) with 216 community-dwelling older
adults with MCI, as determined by a baseline Montreal
Cognitive Assessment (MoCA) score < 26/30, with subjective memory complaints (SMC), without significant functional impairment, and no dementia (Clinical
Dementia Rating (CDR) < 1.0) [42, 43], aged 65 to 85
years, living in Metro Vancouver, BC, Canada. This study
will include a 6-month intervention and a 12-month follow-up (i.e., 18 months from baseline; Fig. 1). There will
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be a dedicated research coordinator (non-blinded) and
trained assessors (blinded). Standardized protocols will
be developed, and study personnel will be trained by the
research team. Assessments and exercise sessions will
occur at a research laboratory on the Vancouver General
Hospital campus, Vancouver, Canada.
Recruitment

Individuals will be recruited from both the community,
with advertisements placed in community centers and
newspapers in Greater Vancouver, and from the University of British Columbia Hospital Clinic for Alzheimer’s Disease and Related Disorders. All individuals who
receive care at the clinic have the option to sign a consent
form providing access to their records for research purposes and indicating their willingness to be approached
for research studies. Individuals interested in participating will be screened by telephone to check for eligibility
based on our inclusion and exclusion criteria, and the
Physical Activity Readiness Questionnaire for Everyone
(PAR-Q Plus) [44], a screening measure of physical readiness for exercise. Research staff will invite eligible participants to attend a consent and screening session, either
over the phone or in-person, during which details of the
study will be provided.
Time frame

Participant enrollment began on November 13, 2017,
and the final assessment is anticipated to be completed
by December 2023. The COVID-19 pandemic impacted
recruitment for much of 2020. As of May 25, 2022,
176 individuals (81% of the target sample) have been
recruited and randomized.
Eligibility
Inclusion criteria

We will include community-dwelling females and males
who meet the following inclusion criteria: (1) aged
between 65 and 85 years; (2) have subjective memory
complaints, defined as the self-reported feeling of worsening memory, as determined by a standard question
[45]; (3) have baseline MoCA score of < 26/30 [46]; (4)
have a Mini-Mental State Examination (MMSE) score >
22 [47] and a Clinical Dementia Rating score < 1.0 [43];
(5) do not have any significant impairment in daily function as indicated by a score of > 6/8 on the Lawton and
Brody Instrumental Activities of Daily Living Scale [48];
(6) score < 5/15 on the Geriatric Depression Scale (GDS)
[49]; (7) completed high school education; (8) live in
their own home; (9) read, write, and speak English with
acceptable visual and auditory acuity; (10) not expected
to start, or are stable, on a fixed dose of anti-dementia
medications (e.g., donepezil, galantamine); (11) provide a
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signed and dated informed consent document; (12) able
to walk independently without an aid; (13) in sufficient
health to participate in the exercise programs, based on
their medical history, the PAR-Q Plus [44], and written
approval by their family physician (if required); and (14)
have the capacity to comply with the scheduled assessments and exercise sessions.
Exclusion criteria

We will exclude individuals who are (1) engaged in moderate-intensity aerobic exercise > 60 minutes per week, in
the 3 months prior to study entry; (2) engaged in progressive resistance training > 1×/week in the 3 months prior
to study entry; (3) diagnosed previously with dementia of
any type; (4) clinically suspected to have neurodegenerative disease as the cause of MCI that is not Alzheimer’s
disease, vascular cognitive impairment, or both (e.g.,
multiple sclerosis, Parkinson’s disease, Huntington’s
disease, frontotemporal dementia); (5) at high risk for
cardiac complications during exercise or unable to selfregulate activity or to understand recommended activity
level; (6) diagnosed by their family physician with clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility; (7) on a
new or recent (i.e., less than 3 months from study entry)
or changed dose of medications that may negatively
affect cognitive function, such as anticholinergics (i.e.,
typical and atypical antipsychotics) and anticonvulsants
(e.g., gabapentin, valproic acid); (8) on any hormone
therapy (estrogen, progesterone, or testosterone) in the
last 24 months; or (9) planning to participate, or already
enrolled in, a concurrent clinical drug or exercise trial.
A subset (~40%) of right hand-dominant participants
will undergo magnetic resonance imaging (MRI) scanning. We will exclude participants who do not meet
the specific scanning requirements of the UBC MRI
Research Centre or do not provide consent. Specifically,
participants will be excluded from the MRI scanning if
they have any of the following: pacemaker, brain aneurysm clip, cochlear implant, surgery or tattoos within the
past 6 weeks, electrical stimulator for nerves or bones,
implanted infusion pump, history of any eye injury
involving metal fragments, artificial heart valve, orthopedic hardware, other metallic prostheses, any blood vessel
filter, coil or catheter, ear or eye implant, bullets, or other
metallic fragments.
Sample size considerations

The planned sample size was determined with the aim of
testing the main effects of AT and RT on changes in cognitive function, as assessed by the ADAS-Cog-Plus [50].
In computing the required sample size, we used G*Power
and the sample analytic model in the statistical analyses.
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Unpublished data from a separate set of 96 older adults
with MCI from our laboratory estimated that the correlation between baseline ADAS-Cog-Plus and the same
measure collected 6 months later was approximately 0.80
[51]. This value was used to calculate the assumed residual variance in the analysis of covariance (ANCOVA)
model of 0.36 (i.e., 1 − 0.802). With a targeted enrolment
of 216 individuals and accounting for an overall dropout of 15% (assumed to impact each intervention arm
equally), we will have a power of 0.80 to detect a standardized mean difference (SMD) of 0.27 for the effect of
AT or RT on cognitive function with a two-tailed alpha
of 0.05 applied to each comparison [9]. The SMD of
0.27 concurs with findings from recent meta-analyses
[9, 52, 53]. To detect an interaction between AT and RT
with 0.80 power, the true effect size of 0.53 is required.
Figure 2 depicts the 3 planned primary comparisons to
examine the main and interaction effects of AT and RT.
Our secondary objective is to test whether biological
sex moderates the effect of exercise (AT and RT, separately) on changes in cognitive function, as assessed by
the ADAS-Cog-Plus. We conducted two meta-analyses
[10, 52] and observed an average sex difference, as determined by comparing trials with high versus low proportion of female, in AT (SMD=0.75) and in RT (SMD=0.65)
on executive functions and episodic memory. Using these
values as estimates of the true effect sizes of the biological sex by exercise interaction effects, a total sample size
of 216 (108 men and 108 women) randomly assigned to
one of the four conditions will provide greater than 0.90
power with a two-tailed alpha of 0.05 and accounting for
an overall dropout rate of 15% (assumed to impact each
intervention arm equally).
Data entry

No personal identifiers will be acquired during data collection. All paper-based data will be stored in locked
cabinets and all alphanumeric data will be entered by a
trained study personnel who will conduct range checks
for data values. All alphanumeric data and neuroimaging will be stored on a secured server hosted by UBC. All
data will be deidentified.
Measurements

There will be three key measurement points: baseline, 6
months (trial completion), and 18 months (i.e., 12-month
follow-up). To minimize attrition over the 12-month
follow-up, participants will be contacted at 6 months
post trial completion to complete a set of questionnaires. Baseline measurements will be obtained prior to
randomization. See Fig. 3 for the schedule of all study
measures.

Fig. 2 Schematic representation of the three primary comparisons in
the factorial randomized controlled trial design
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Fig 3 Schedule of enrolment, interventions, and assessments according to the SPIRIT Checklist

Consent and screening session

Subjective memory complaints will be determined
with one verbal yes/no question: “Do you feel like your

memory or thinking is becoming worse?”. Global cognition will be assessed with the MoCA [46] and MMSE
[47]. The Lawton and Brody Instrumental Activities of
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Daily Living Scale and the GDS will also be administered. The Edinburgh Handedness Questionnaire will be
administered to assess handedness [54].
Descriptors

Standing height in centimeters and mass in kilograms will
be ascertained using standardized equipment. General
health, demographics, socioeconomic status, and education will be obtained via questionnaire. The Functional
Comorbidity Index will estimate the degree of comorbidity associated with physical functioning [55]. The GDS
will be used to assess depressive symptoms [49]. The
EPIC-Norfolk Physical Activity Questionnaire will measure physical activity levels [56]. Engagement in cognitive
stimulating activities will be measured with the Florida
Cognitive Activity Questionnaire [57] and the Lifetime
Participation in Cognitively Stimulating Activities [58].
The National Adult Reading Test will be used to estimate
premorbid intellectual functioning [59]. The Reproductive History Questionnaire will assess reproductive histories of participants [adapted from [60]]. To examine
potential genetic moderation of exercise efficacy, we will
take a targeted approach for common single-nucleotide
polymorphisms that have previously been implicated
in cognitive aging and exercise-induced cognitive gains
(e.g., BDNF Val66Met polymorphism, APOE4) [11, 61].
DNA will be extracted from whole blood by standard
protocol, and genotype will be determined by a TaqMan
by-design assay.
Primary outcome

Our primary measure will be the ADAS-Cog-Plus [50].
The ADAS-Cog-Plus uses a multidimensional item
response theory model to generate a global cognitive
score from the 13-item ADAS-Cog [62] and additional
standard cognitive assessments. For this trial, we will use
the 13-item ADAS-Cog (0-85 points), Trail Making Tests
(Parts A and B), Digit Span Forward and Backward, Digit
Symbol Substitute Test, animal and vegetable fluency,
Rey Auditory Verbal Learning Test, and Clock Drawing test as the input variables into the scoring algorithm.
Lower ADAS-Cog-Plus scores represent better cognitive
performance; scores range from −1.0 to +1.0 [e.g., −1.0
indicates healthy cognitive functioning, 0.0 indicates
MCI, and +1.0 indicates dementia [63]].
Secondary outcomes

Cognitive function A battery of computerized and
standardized paper and pen neuropsychological tests
will be used to assess different cognitive domains.
The computerized battery will include the National
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Institutes of Health Toolbox Cognition Battery [64, 65],
a comprehensive neuropsychological battery with normative values. Specifically, we will use its (a) Dimensional Change Card Sort Test to measure set shifting;
(b) Flanker Inhibitory Control and Attention Test to
measure response inhibition and attention; (c) List Sorting Working Memory Test to measure working memory; and (d) Picture Sequence Memory Test to measure
episodic memory. Spatial memory will be measured
with a computerized paradigm [66]. The task requires
participants to recall the spatial location of one, two,
or three dots presented on a computer screen. Reaction
time and accuracy will be recorded.
Standardized paper and pen neuropsychological tests will
assess executive functions, verbal fluency, visual memory,
prospective memory, and visuospatial ability. Specifically, the battery will include the individual components
of ADAS-Cog-Plus, such as the 13-item ADAS-Cog,
Trail Making Tests (set shifting), Digit Span Forward
and Backward (working memory), Digit Symbol Substitution Test (processing speed), animal and vegetable fluency (verbal fluency), Rey Auditory Verbal Learning Test
(verbal memory), and Clock Drawing. For the 13-item
ADAS-Cog, a change of 3.0 points is a minimally important difference [67]; higher scores on the 13-item ADASCog indicate greater cognitive impairment (range 0–85
points).
In addition, we will administer the Stroop Colour Word
Test to assess response inhibition and selective attention
[68]. Visual memory will be assessed by the Rey-Osterrieth Complex Figure Test [69]. Prospective memory, the
ability to remember and perform an intended action at a
specific time in the future, will be assessed by the Prospective Memory Test [70]. We will use the Judgement of
Line Orientation to test visuospatial skills [71].
Health‑related quality of life and wellbeing We will
evaluate health-related quality of life using the EuroQol-5
Domain-5 Level (EQ-5D-5L) [72]. This is a preferencebased utility instrument that provides weightings for
quality-adjusted life years (QALYs). A QALY is a metric
used to assess health-related quality of life that captures
both quality and quantity of time spent in a particular
health state [73]. The EQ-5D-5L captures 243 unique
health states based on the following domains: mobility,
self-care, usual activities, pain, anxiety, and depression. A
score of zero indicates death while a score of 1 indicates
full health. The EQ-5D-5L also consists of a visual analog
scale that records the individual’s self-related health on a
vertical visual analog scale.
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We will evaluate wellbeing using the ICEpop CAPability
Measure for Older adults [74, 75]. This assesses wellbeing across five attributes: (1) attachment (love and friendship); (2) security (thinking about the future without concern); (3) role (doing things that make you feel valued);
(4) enjoyment (enjoyment and pleasure); and (5) control
(independence). A score of zero indicates no capability
while a score of 1 indicates full capability.
Physical function Cardiorespiratory fitness will be
estimated with the modified Balke submaximal-graded
exercise treadmill test [76], with heart rate continuously monitored. Participants will walk on the treadmill
at a pre-determined speed (females 4.8 km/h; males 5.3
km/h) until they reach volitional fatigue or 70% of heart
rate reserve (HRR). The Short Physical Performance Battery will assess general balance and mobility [77]. Participants are assessed on performance of standing balance,
walking, and sit-to-stand. Each component is rated out of
4 points, for a maximum of 12 points. A score of < 9/12
predicts subsequent disability [77]. Participants will also
complete the 400-m Walk [78]. Participants will be asked
to walk 400 m as quickly as they can without running and
time to complete will be recorded.
Muscular strength will be examined separately for the
upper and lower body. Upper body strength will be
assessed using the bilateral hand dynamometer grip
strength test. Lower body strength will be assessed using
the Biodex bilateral concentric knee extension and flexion strength test. The peak torque a participant is able to
achieve will be recorded for each leg for both concentric
extension and flexion. Additionally, lower body strength
will be measured with the 30-s sit-to-stand test [79]; participants will be asked to complete as many full sit-tostands as possible within 30 s.
Body composition will be assessed with a full-body dualenergy X-ray absorptiometry (DEXA) (Hologic, Mississauga, ON, Canada) scan. We will use DEXA-derived
total body fat mass (g), total body lean mass (g), and body
composition (% of fat and lean mass).
Actigraphy measures Objective measures of sleep
quality will be estimated over a 7-day period using the
MotionWatch8© wrist-worn actigraphy unit (CamNtech;
Cambridge, UK) to estimate sleep duration, latency, and
fragmentation. Participants will also be asked to complete the Consensus Sleep Diary each morning [80]. In
addition to sleep quality, the MotionWatch8© will also
be used to calculate daily physical activity. The number of
minutes spent in moderate to vigorous physical activity
(>3.0 METs) is compared to the total time spent awake
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and out of bed to determine the percentage of waking
hours each day spent in moderate to vigorous intensity
physical activity [81].
Questionnaires and falls Standardized questionnaires
will be administered to assess anxiety [82], depression
[83], sleep quality [84], sleep apnea risk [85], life space
mobility [86], everyday memory [87], mindfulness [88],
physical activity [89], sedentary behavior [90], social
network [91], social provisions [92], loneliness [93], and
health care costs [94]. Falls will be prospectively monitored via monthly calendars. See Table 1 for more details.
Tertiary outcomes

Brain structure and function In a subset of participants
at baseline and trial completion at 6 months, MRI will
be conducted at the UBC MRI Research Centre using
a Philips Achieva 3.0T MRI scanner with a 32-channel sensitivity encoding head coil (SENSE factor=2.4)
and parallel imaging. High-resolution structural imaging will include two three-dimensional 1-mm isotropic
T1 MPRAGE (TR=2530 ms, TE=3.04 ms, TI=800 ms,
flip angle=10°, FOV=256×256×220 mm) that will be
averaged during post-processing and two 1-mm isotropic T2 (SPACE) images (TR=4000 ms, TE=406 ms,
flip angle=90°, FOV=260×228×176 mm). T1 images
will be used for co-registration of individual participant
functional MRI (fMRI) data into a standard stereotaxic
space and for ascertaining changes in cortical thickness,
and cortical and sub-cortical brain volumes. To allow the
assessment of white matter hyperintensities (WMHs),
we will acquire two sequences of T2-FLAIR. An Automated Labeling Pathway [95] will be used to quantify
volumes and localization of focal WMHs. We will also
use a 60-directional diffusion tensor image with a single
shot echo-planar imaging (EPI) sequence (TR=7013 ms,
TE=60 ms, FOV=224×224 mm, 70 slices, 2.2-mm slice
thickness, voxel dimension=2.23 mm, b=700 s/mm2)
and 5 non-weighted diffusion weighted images (b=0),
with a focus on measuring fractional anisotropy, mean
diffusivity, axial diffusion, and radial diffusion [96]. Sixtydirection acquisition will also generate the needed resolution for fiber-tracking. Functional network organization will be evaluated with resting-state functional MRI.
EPI data will be acquired with slices in an oblique 30°
orientation relative to main magnetic field to optimize
signal in ventral frontal regions (TR=2000 ms, TE=30
ms, flip angle=90°, FOV=220×220 mm, 3.4×3.4×3.5
mm2 voxels). We will collect an additional 13-min scan to
maximize test-retest reliability [97]. During resting state
scans, participants will be instructed to keep their eyes
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Table 1 Psychosocial assessments and other questionnaires
Name

Description

State and Trait Anxiety Inventory (STAI) [82]

A 40-item questionnaire assessing mood and anxiety.

Center for Epidemiologic Studies Depression Scale (CES-D) [83] A 20-item questionnaire measuring symptoms associated with depression experi‑
enced in the past week.
Pittsburgh Sleep Quality Index (PSQI) [84]

A 19-item questionnaire assessing sleep quality in the previous month using subjec‑
tive ratings for 7 different components (i.e., sleep quality; sleep latency; sleep duration;
habitual sleep efficiency; sleep disturbance; use of sleeping medication; and daytime
dysfunction).

STOP Bang Questionnaire [85]

An 8-item questionnaire assessing obstructive sleep apnea risk.

Life Space Questionnaire [86]

A 6-item questionnaire to measure the extent of mobility of older adults.

Everyday Memory Questionnaire (EMQ) [87]

A 28-item questionnaire assessing memory failures over the past 3 months.

Mindfulness Attention Awareness Scale (MAAS) [88]

A 12-item questionnaire assessing mindfulness during daily activities such as conversa‑
tion, commuting, and eating.

CHAMPS Physical Activity Questionnaire for Older Adults [89]

A 41-item questionnaire assessing weekly frequency and duration of physical activities
relevant for older adults.

Sedentary Behaviour Questionnaire (SBQ) [90]

A questionnaire assessing time spent in 9 sedentary behaviors during a weekday and
weekend.

Lubben Social Network Scale – Revised (LSNS-R) [91]

A 12-item questionnaire assessing social engagement with family and friends.

Social Provisions Scale (SPS) [92]

A 24-item scale measuring the availability of social support.

UCLA Loneliness Scale [93]

A 20-item scale assessing feelings of loneliness and social isolation.

Health Care Resource Utilization (HRU) [94]

A 10-item questionnaire that asks participants about health care visits, services, and
ability to do chores for the calculation of economic burden.

open, look at a fixed point on a screen, and remain awake.
We will also collect a letter n-back working memory taskevoked EPI scan as well as Relational and Item Specific
Encoding and Recognition task-evoked EPI scans [98].
Preprocessing of the fMRI data will entail rigid body
motion correction, spatial smoothing, band-pass temporal filtering to exclude confounding physiological signals, followed by an Independent Component Analysis
based Automatic Removal of Motion Artifacts to remove
motion-related artifacts. Preprocessed resting-state timeseries will be extracted from a priori selected networks
of interest masks based on the Yeo 7+ Networks [99] or
parcellated regions of interest based on established functional atlases and cross-correlated with every voxel in the
brain to establish functional connectivity maps. For preprocessed task-based fMRI data, within- and betweensubject differences in task-evoked neural activity will be
calculated via fixed effects and mixed effects modelling.
Cardiometabolic risk factors We will assess arterial
stiffness, blood pressure, body mass index, and fasting
serum glucose and lipid profile. Arterial stiffness will be
measured by carotid-femoral pulse wave velocity. Pulse
wave velocity will be measured using a Complior DE1210
ultrasound machine (Alam Medical, Saint Quentin Fallavier, France) with the participants lying supine and
rested for at least 5 min. Resting systolic and diastolic
blood pressure will be recorded in duplicate, using a voscillometric sphygmomanometer, the Omron HEM-775.

Values will be presented as a mean of two recordings that
are taken 1 min apart. Participants will rest seated with
their back supported, feet flat on the floor, and arms supported at heart level for 5 min prior to blood pressure
measurements. Body mass index will be calculated as
mass in kg/height in m2. Fasting serum glucose and lipid
profile (e.g., total serum cholesterol, triglycerides, highdensity lipoprotein, low-density lipoprotein, HbA1C) will
be measured by conventional laboratory methods.
Hypothalamic‑pituitary‑adrenal
axis
function To
assess hypothalamic-pituitary-adrenal axis activity, we
will measure the stress hormone cortisol to examine (1)
total cortisol concentration over the day (area under the
curve); (2) cortisol awakening response, a distinct aspect
of the circadian cortisol profile; and (3) changes in cortisol response to engaging in an exercise session with time
of day held constant. Free cortisol levels will be assessed
in salivary samples (Salivettes) collected 5× each day (at
awakening, +30 min, 2 pm, 4 pm, bedtime) for 2 days at
baseline and trial completion at 6 months. As well, salivary samples will be collected immediately before and
immediately after the exercise session within the first 2
weeks of exercise training and within the last 2 weeks of
exercise training to examine cortisol response to exercise.
Blood biomarkers Fasting blood will be collected in the
morning at baseline and at trial completion at 6 months
from all consenting participants. Blood will be processed
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and stored at −80 °C as plasma, serum, and whole blood
in a secure research facility. The main analytes of interest include neurotrophic factors, myokines, sex steroid
hormones, and pro- and anti-inflammatory cytokines.
Remaining blood samples will be stored for 5 years from
collection. If there are remaining samples after 5 years
and are felt to be still useful for other studies, a separate
ethics application will be submitted to explain the nature
of its use. Otherwise, the samples will be destroyed after
5 years from collection.

cool down. To ensure fidelity across different instructors and across time, detailed protocols with pictures will
be provided during instructor training. Sessions will be
regularly audited by the study coordinator with standard checklists to ensure intervention content is delivered
accurately and consistently. For each AT, RT, or BAT
session, exercise instructors will record attendance and
participation (i.e., did participant complete all components of a given session). Borg’s Rating of Perceived Exertion (RPE) [100] will be monitored at standard intervals
throughout each AT, RT, and BAT session.

Treatment allocation
Randomization

AT program

After the baseline assessment, participants will be randomly assigned (1:1:1:1) to one of four experimental
groups (Fig. 1). Randomization will be performed using
the “randomizeR” package in R (Uschner et al. 2018). The
randomization sequence will be stratified by biological
sex with equal probability (1:1:1:1) random assignment to
one of the four experimental groups: (1) 4×/week balance
and tone (BAT; i.e., active control); (2) combined 2×/
week AT + 2×/week RT (AT+RT); (3) 2×/week AT +
2×/week BAT (AT); or (4) 2×/week RT + 2×/week BAT
(RT). Permuted blocks of size 12 will be used to ensure
balance. To ensure blinding, the randomization sequence
will be generated away from study personnel and held in
a password-protected file on a secure university server
and accessed only by a member of research staff who is
not involved in this study.
Allocation concealment

Participant recruitment and enrollment will be managed by research personnel who will screen for eligibility, acquire consent, and conduct baseline assessments.
Randomization to an intervention group will occur after
completion of the baseline assessments. Research personnel conducting assessments and analyses will be blinded
to group allocation. We will not be able to blind participants or research personnel delivering the interventions
and obtaining the monthly physical activity questionnaire
data. Blinding will be supported by providing explicit
instructions to the research personnel and participants
not to discuss issues related to physical activity during
the assessments.
Experimental groups

All participants will attend four 60-min sessions each
week for 6 months (i.e., 26 weeks). All sessions will have
a participant to instructor ratio of 4:1, with a maximum
of 12 participants per session and will be led by certified
exercise instructors. Each AT, RT, or BAT session will
include a 10-min warm-up, 40min training, and a 10-min

The progressive moderate-intensity AT program has
been used in prior trials and improved cognitive function
in older adults with MCI [101, 102]. The AT program
involves a series of standardized exercise stations, including treadmills, stationary cycles, aerobic steppers, agility ladders, and non-contact boxing. Participants rotate
through each station within the 40-min training duration
with 1-min rest between stations. Participants will exercise initially at approximately 50% of their age specific
target HRR and gradually progress to reach the target of
80% of HRR. Exercise intensity during AT sessions will be
monitored via heart rate monitors and the 20-point RPE
[100]. Participants will gradually progress to a target RPE
of 16 to 17.
RT program

The RT program has been used in prior trials and
improved cognitive function in older adults [102, 103].
It is designed to significantly improve muscular strength
using pressurized air system and free weights to provide
the training stimulus. Pressurized air system exercises
will consist of triceps extension, seated row, latissimus
dorsi pull downs, leg press, and hamstring curls. Free
weighted exercises will consist of bicep curls, standing
calf raises, wall squats, and wall push-ups.
The first 6 weeks of the RT program will focus on orienting participants with resistance training and familiarizing them with proper technique. The initial intensity of
the training stimulus will be set to a weight where participants can complete 2 sets of 10–15 repetitions. Training
intensity will then progress on a cyclic basis from 45 to
85% of predicted 1 repetition maximum (1RM) as determined at week 6 using an 8-repetition maximum (8RM)
test. Every 4 weeks, the 8RM test is repeated and the
cycle repeats.
BAT program

The BAT program has been used in prior exercise trials
as an active control [102–104]. It is a low-intensity program consisting of stretching exercises, range of motion
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exercises, static balance exercises (e.g., tandem balance,
single leg balance), and functional strength exercises (e.g.,
sit to stand). Other than bodyweight and the occasional
use of light resistance bands (e.g., 2 lbs or less), no additional loading (e.g., hand weights) will be applied to any
of the exercises. There is no evidence that these exercises
improve cognitive function [102, 103], and this group will
serve to control for known and unknown confounding
variables.
Intervention adherence

Session attendance will be recorded by the instructors
and adherence will be defined as the percentage of the
total sessions attended.
Data and adverse event monitoring

A Data and Safety Monitoring Committee will be established by co-investigators who will be independent from
the day-to-day conduct of the study. They will review
all adverse events on a quarterly basis and will classify
them based on the definitions from the January 2007
OHRP Guidance on Reviewing and Reporting Unantici‑
pated Problems Involving Risks to Subjects or Others and
Adverse Events, OHRP Guidance (see link). The Committee will stop the study if the data are of sufficient concern
(e.g., increased rate of falls as a result of the intervention).
All adverse events will be reported to this Committee and
if required, to the relevant university and health authority
ethics boards by the study coordinator. There is no anticipated harm or compensation for trial participation.
Statistical analyses

Initial descriptive analyses will compute percentages,
mean, or median values for baseline characteristics for
each of the treatment arms. Next, missing data will be
examined to identify the nature of missing data. Even if
data are missing completely at random, missing data will
be imputed to improve statistical power using multivariate imputation by chained equations [105]. Forty imputed
data sets will be created following 40 iterations of a Gibbs
sampler for each imputed data set. Proper convergence of
the Gibbs sampler will be confirmed by visual inspection
of trace plots of each imputed variable, to ensure proper
mixing and the absence of spikes or systematic trends
across iterations. Analyses will be pooled across the 40
imputed data sets.
The primary analysis will be performed according to
the intention-to-treat principle and entail mixed effects
ANCOVA to test the main effects of AT and RT, as
well as the interaction effect of AT × RT (see Fig. 2) on
changes in cognitive function, as assessed by the ADASCog-Plus. The ANCOVA model will use the repeatedly
measured (6-month and 18-month) ADAS-Cog-Plus

Page 11 of 16

performance as the dependent variable; baseline ADASCog-Plus score, biological sex, AT, RT, and AT × RT as
independent, fixed effects variables. Furthermore, to
model changes in the outcome between months 6 and
18, and to estimate distinct treatment effects at months
6 and 18, a fixed main effect of time and all interactions
between time and the independent variables will be
included. To account for the dependency in the repeatedly measured outcome, a random subject-level intercept
will be included. Month 6 will be considered the primary
endpoint and month 18 will be considered the secondary
endpoint. Secondary analyses of the primary outcome
will examine the interaction between biological sex and
effects of AT, RT, and AT × RT. A two-tailed alpha of
0.05 will be used for each comparison (i.e., uncorrected
alpha).
Secondary outcomes will be examined using identical
random-effects ANCOVA models as those constructed
with the primary outcome.
Mediation and moderation

Mediation analysis will test for potential mediators of
the relationship between the primary effects of exercise
training (i.e., AT, RT, and AT × RT) and the outcome of
interests (e.g., ADAS-Cog-Plus) [106]. The mediation
effect will be quantified by the product of (1) the estimated effect of exercise training on the mediator, and
(2) the estimated effect of the mediator on the outcome
of interest. This product and its 95% confidence interval
will be estimated using bootstrapping of the mediation
model. To examine potential moderators (i.e., biological
sex, genotype) of the relationship between exercise training and the outcome of interest, we will incorporate the
potential moderator in the random-effects ANCOVA,
including the main effect of the moderator and its interaction with the effects of AT, RT, and AT × RT.
Economic evaluation

The economic evaluation will examine the efficiency of
three exercise interventions compared with BAT as well
as ranking the relative cost-effectiveness of each of the
three exercise interventions [107, 108]. The outcome
of our cost–utility analysis is the incremental cost–utility ratio (ICUR): ICUR = ΔCost/ΔQALYs; QALYs, estimated from the EQ-5D-5L, represent time and quality
spent in given health states.
Modifications due to Covid‑19 pandemic

In response to the COVID-19 pandemic and the restrictions put in place by the British Columbia government
and UBC, all in-person research activities were halted on
March 19, 2020. In-person research and enrollment of
new participants were allowed to gradually resume as of
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August 11, 2020. In-person exercise sessions resumed at
a limited capacity on September 28, 2020.
During this period of time, modifications were made to
the protocol to allow the research team to continue the
trial with enrolled participants. The modifications were
done in two phases. Phase 1 modifications were implemented from March 19, 2020, until June 1, 2020. Phase 2
modifications were implemented from June 1, 2020, until
August 11, 2020, when we resumed in-person assessments, or until September 28, 2020, when we resumed
in-person exercise sessions. These modifications included
the following:
(i) In-person, group-based exercise sessions were
transformed into home-based exercise programs.
Participants were provided with detailed exercise
manuals with pictures and exercise calendars. The
exercise calendars were used to track adherence
as well as to record exercise intensity, using the
Borg’s RPE [100]. For Phase 1, participants in the
RT and AT+RT groups were given TheraBands
and no other equipment was given. For Phase 2, the
home-based exercise programs were augmented
with YouTube exercise videos. For those without
internet access, DVD’s were made and provided.
In addition, RT participants were provided with
weighted resistance bands, AT participants were
given Fitbit Inspire HR (USA) fitness trackers to
monitor heart rate during AT sessions, and BAT
participants were given yoga balls. Weekly phone
calls were made to answer any questions as well as
to monitor any adverse events and falls. In Phase 2,
exercise logs were provided to all participants. For
RT, the weight used for each exercise, the number
of reps and sets, and the RPE after each RT exercise
were recorded. For AT, RPE as well as Fitbit measured heart rate were recorded at the beginning, in
the middle, and at the end of each AT session. For
BAT, the overall RPE was recorded per session.
(ii) All participants were contacted by phone twice
per week. During these phone calls, instructors
answered any questions, promoted adherence, and
progressed RT and AT exercises when appropriate.
Adverse events and falls were also tracked during
these phone calls.
(iii) A total of 28 participants completed their intervention prior to August 11, 2020. To conduct their
assessments, the research team revised the protocol
to allow virtual measurement, where possible. We
preloaded iPads with Zoom and delivered it with
assessment packages (with instructions) to participants’ homes. Prior to implementation, the research
team practiced and refined the virtual measurement
protocol. All cognitive assessments were completed
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except for the (a) National Institutes of Health Toolbox List Sorting Working Memory Test; (b) spatial memory computerized test; (c) Rey-Osterrieth
Complex Figure Test, and (d) Prospective Memory
Test. For physical function measures, we measured
the Short Physical Performance Battery, 400-m
Walk, and 30-s sit-to-stand. We also provided a
blood pressure monitor and had participants measure their blood pressure and heart rate while on
Zoom. A total of 8 participants completed both
their cognitive and physical assessments via Zoom.
Another 5 participants completed their cognitive
assessment in person but their physical assessment
via Zoom. From June 24, 2020, to August 11, 2020,
we received permission to conduct a limited number of in-person assessments. A total of 15 participants were assessed with appropriate social distancing and personal protective equipment being used.
All cognitive assessments and a select number of
physical assessments were completed.
(iv) Blood draws were not completed from June 1,
2020, to August 11, 2020. Saliva and MW8 data
collection continued without any modifications.
Our 3T MRI Research Centre remained open
throughout the pandemic with extra safety measures
implemented, and thus, neuroimaging continued as
long as participants were comfortable to do so.
On August 11, 2020, in-person assessments and blood
draws resumed with approved safety protocols. On September 28, 2020, in-person exercise sessions resumed
with approved safety protocols, including restrictions
on occupancy. As AT and RT are of moderate intensity,
to reduce the risk of COVID-19 among our participants
while trying to preserve training fidelity, from August 11,
2020, to April 4, 2022, the four experimental groups were
delivered using a hybrid model. In this hybrid model, participants completed two exercise sessions in person and
completed two sessions at home each week. Specifically,
the AT group completed AT sessions in person and BAT
sessions at home. The RT group completed RT sessions
in person and BAT sessions at home. The AT+RT group
completed one AT and one RT session in person, and one
AT session and one RT session at home. The BAT group
completed two BAT sessions in person and two BAT sessions at home. Participants were provided with exercise
manuals, YouTube videos, and exercise equipment. Exercise equipment included Fitbit Inspire HR fitness trackers,
steppers, and agility cones for AT and weighted resistance
bands for RT. Yoga balls were provided for BAT. Exercise
logs were audited bi-weekly by exercise instructors.
We will conduct additional statistical analyses to
compare our primary outcome (ADAS-Cog-Plus)
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between the participants whose training was significantly modified due to the COVID-19 pandemic.

Discussion
We have assembled a unified, transdisciplinary, and
experienced team to use a multi-pronged approach to
assess the individual effects of AT and RT, as well as the
interaction effect of combining the two types of exercise
training on cognitive function and determine the possible underlying biological mechanisms in older adults
with MCI. We expect that at the end of the 6-month
intervention, compared with BAT, both AT and RT
will demonstrate improved performance on the ADASCog-Plus, in specific cognitive domains (i.e., executive
functions and episodic memory), and in health-related
quality of life, with the greatest improvements seen in
the combined AT and RT group. We also hypothesize
that the effects of AT and RT will be moderated by biological sex and genotype with greater AT benefits seen
in females and those without the BDNF Val66Met polymorphism and greater RT benefits seen in males and
in BDNF Val66Met polymorphism carriers.
Our study has some limitations that should be taken
into consideration. Given our selection criteria, we will
include older adults with MCI due to Alzheimer’s disease, vascular cognitive impairment, or both. Thus, our
sample will be heterogeneous; however, this will increase
the generalizability of our results. Despite the rigorous
cognitive assessments included in our study, to ultimately
appreciate the role of exercise in dementia prevention, studies that follow dementia progression rates are
needed. Our study will provide critical data for future
intervention trials powered to assess dementia progression rates as their primary outcome. We were unable to
assess the sample size requirements for each of our secondary or tertiary outcomes. Thus, some of these outcomes will be underpowered.
This 2×2 RCT addresses the problem of how to effectively minimize cognitive decline among older adults
with MCI—a population at increased risk for dementia—
with different types of exercise. Establishing the efficacy
of different types and combinations of exercise training
will advance our understanding of how to best prescribe
exercise to attenuate cognitive decline. Ultimately, our
study results will allow decision makers to leverage the
financial support needed for readily accessible and tailored community-based interventions to promote cognitive health and combat dementia.
Trial status

This protocol is version 10, updated September 16,
2021. Participant enrollment began on November 13,
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2017, and recruitment is anticipated to be completed
by June 2023. Any changes to the protocol will be documented by the principal investigator and all research
personnel will be notified. The clinical trial registration
will be amended for all updates to the protocol.
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